Abstract
Rupatadine, a new antihistamine with dual antagonistic activity against platelet-activating factor (PAF) and histamine H1 receptors, can inhibit inflammatory reactions by affecting allergic reactions at different stages. It has a rapid onset of action and a long-lasting effect, so once-daily dosing is recommended. Clinical studies have shown that low-dose oral rupatadine can effectively control the symptoms of seasonal and perennial allergic rhinitis. Recent researches have demonstrated that it has good effect on some skin diseases such as chronic idiopathic urticaria and cold urticaria with good tolerability. Key words: Urticaria; Histamine agents; Pharmacologic actions; Therapeutic uses; Safety
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
